5/17
07:44 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.
5/17
05:19 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
5/17
05:19 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
5/14
08:01 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
5/14
08:01 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.
5/14
05:10 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/26
12:38 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/26
12:38 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/26
08:47 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/25
06:47 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/25
06:47 pm
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/25
11:35 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/25
11:35 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/25
11:21 am
bmrn
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
4/25
10:33 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/25
10:14 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
4/25
10:14 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN